Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Autoimmune diseases like rheumatoid arthritis involve problematic cytokine production.
• Targeting cytokine production is a promising but underdeveloped therapeutic strategy.

Purpose of the Study:

• To investigate the therapeutic potential of soluble CD83 (sCD83) in resolving autoimmune antigen-induced arthritis (AIA).
• To elucidate the underlying mechanisms of sCD83's action in reducing inflammation and joint damage.

Main Methods:

• Treatment of AIA mice with sCD83.
• Measurement of cytokine levels (IL-17A, IFNγ, IL-6, TNFα) and RANKL expression in joints.
• Assessment of osteoclast differentiation and bone destruction.
• Inhibition studies using 1-methyltryptophan (IDO inhibitor) and anti-TGF-β antibodies.
• Analysis of regulatory T cell populations.

Main Results:

• sCD83 significantly reduced pro-inflammatory cytokines and RANKL expression in the joints of AIA mice.
• sCD83 inhibited osteoclast differentiation and subsequent joint destruction.
• The therapeutic effects of sCD83 were dependent on indoleamine 2,3-dioxygenase (IDO) and transforming growth factor-beta (TGF-β).
• sCD83 treatment led to an increase in regulatory T cells.

Conclusions:

• Soluble CD83 (sCD83) effectively resolves autoimmune arthritis by downregulating key inflammatory mediators.
• The mechanism involves IDO and TGF-β, leading to reduced joint damage and increased regulatory T cells.
• sCD83 presents a promising therapeutic strategy for autoimmune and inflammatory conditions.